Skip to main content
SpringerLink
Log in

Docetaxel has been approved by the UK National Institute for Health and Clinical Excellence (NICE),

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. NICE.NICE approves docetaxel as a treatment option for men with advanced prostate cancer. Media Release: 28 Jun 2006. Available from: URL: http://www.nice.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Docetaxel has been approved by the UK National Institute for Health and Clinical Excellence (NICE),. Pharmacoecon. Outcomes News 507, 2 (2006). https://doi.org/10.2165/00151234-200605070-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605070-00003

Keywords

Search

Navigation